After carefully reading the Information Memorandum, taking into account the risk profile therein and considering their suitability to undertake such risk, qualified investors may subscribe to fully paid ordinary shares in Cannadol Pharmaceuticals Ltd. by completing the Subscription Agreement.

To receive the Information Memorandum and Subscription Agreement please submit your name and email below.